JP Morgan Maintains Overweight on BeiGene, Raises Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Jessica Fye maintains an Overweight rating on BeiGene (NASDAQ:BGNE) and raises the price target from $194 to $200.
August 20, 2024 | 2:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan has reaffirmed its Overweight rating on BeiGene and increased the price target from $194 to $200, indicating a positive outlook.
The increase in price target from $194 to $200 by JP Morgan suggests a positive outlook for BeiGene, likely leading to a short-term increase in stock price. The Overweight rating indicates confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100